Global beauty giant L’Oréal signed a contract on June 29 with domestic biotech firm OliX to discover “short interfering ...

Fungal infections are on the rise globally. According to a study by the Manchester Fungal Infection Group, in 2022, approximately 6.5 million people were infected by a pathogenic fungus, and about 3.8 ...

A new possibility for managing cardiovascular disease through RNA interference (RNAi) gene therapies. As cardiovascular diseases continue to be the leading cause of death globally, this technology ...

DURING THE covid-19 pandemic new vaccines were rolled out with unprecedented speed. The fastest to arrive were jabs built from molecules of messenger RNA (mRNA) designed to teach the body how to fight ...

Ionis is a leader in RNA-based therapies, and its spinal muscular atrophy drug Spinraza, marketed by partner Biogen, is the first RNA-based therapy to achieve blockbuster status. The firm's antisense ...

Ionis is a leader in RNA-based therapies, and its spinal muscular atrophy drug Spinraza, marketed by partner Biogen, is the first RNA-based therapy to achieve blockbuster status. The firm's antisense ...

LONDON, Feb 26 (Reuters) - Britain's Ark Therapeutics said on Thursday it had filed a patent application for a new genetic technique that represents an advance in so-called RNA interference technology ...

Decaffeinated coffee is increasingly popular because it lacks the stimulatory effects of caffeine that can trigger palpitations, increased blood pressure, and insomnia. Currently, coffee is ...

With the support of two new funding sources — including a gift from a Brown trustee and a grant from the National Institutes of Health — Brown is expanding RNA research on campus in a continued effort ...